Related Experiment Video

Updated: Apr 16, 2026

Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye
06:10

Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye

Published on: March 30, 2020

8.5K

Anti-VEGF Drugs in Eye Diseases: Local Therapy with Potential Systemic Effects

Markus van der Giet1, Cornelia Henkel, Mirjam Schuchardt

  • 1Charite - Campus Benjamin Franklin, Med. Klinik mit SP Nephrologie, Hindenburgdamm 30, 12203 Berlin. Markus.vanderGiet@charite.de.

Current Pharmaceutical Design
|February 26, 2015
PubMed

Insights

Anti-vascular endothelial growth factor (VEGF) therapies are effective for eye diseases but can cause systemic side effects like hypertension. Careful monitoring is crucial for patients receiving anti-VEGF treatments.

Area of Science:

  • Ophthalmology
  • Oncology
  • Vascular Biology

Background:

  • Vascular endothelial growth factor (VEGF) is a key pro-angiogenic factor.
  • VEGF signaling pathway inhibition is a validated cancer treatment.
  • Local anti-VEGF therapy is established for several proliferative eye diseases.

Purpose of the Study:

  • To review the VEGF system and its role in proliferative eye diseases.
  • To discuss locally administered anti-VEGF drugs.
  • To summarize local and systemic side effects of anti-VEGF therapies.

Main Methods:

  • Literature review of VEGF system and anti-VEGF therapies.
  • Summary of clinical data on anti-VEGF drug efficacy and safety.
  • Analysis of local and systemic adverse events.

Main Results:

  • Anti-VEGF therapies show efficacy in treating conditions like diabetic retinopathy and macular degeneration.
  • Systemic administration of anti-VEGF drugs is associated with adverse effects such as hypertension and renal disorders.
  • Long-term systemic effects may occur even with limited drug resorption.

Conclusions:

  • The VEGF system is a delicate balance, and its disruption can lead to adverse outcomes.
  • Local anti-VEGF therapy is beneficial for specific eye diseases but requires careful consideration of potential systemic risks.
  • Further clinical studies are needed to fully understand the long-term systemic effects of anti-VEGF treatments.

More Related Videos

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization05:14

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Published on: August 11, 2023

1.7K
Subconjunctival Administration of Adeno-associated Virus Vectors in Small Animal Models06:16

Subconjunctival Administration of Adeno-associated Virus Vectors in Small Animal Models

Published on: March 16, 2022

3.8K

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.7K
Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.7K
Ophthalmic Drug Delivery Systems01:23

Ophthalmic Drug Delivery Systems

Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
252
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
4.0K